Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.

[1]  C. Sweet,et al.  Pathogenicity of influenza virus , 1980, Microbiological reviews.

[2]  R B Couch,et al.  Immunity to influenza in man. , 1983, Annual review of microbiology.

[3]  F. Liew,et al.  Cross‐protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity , 1984, European journal of immunology.

[4]  B. Stoll,et al.  Enterotoxigenic Escherichia coli diarrhea in an endemic area prepares the intestine for an anamnestic immunoglobulin A antitoxin response to oral cholera B subunit vaccination , 1988, Infection and immunity.

[5]  T. Nagamine,et al.  Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. , 1988, Vaccine.

[6]  T. Nagamine,et al.  Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine. , 1989, Vaccine.

[7]  T. Nagamine,et al.  Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. , 1990, Vaccine.

[8]  T. Nagamine,et al.  Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza. , 1990, Vaccine.

[9]  T. Kurata,et al.  Superior cross‐protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine , 1992, European journal of immunology.

[10]  T. Nagamine,et al.  Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine. , 1994, Vaccine.

[11]  Hidehiro Takahashi,et al.  Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. , 1996, Journal of immunology.

[12]  J. Wilschut,et al.  Musosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: Induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen , 1998 .

[13]  K. Nichol,et al.  Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. , 1998, Archives of internal medicine.

[14]  E. Kohli,et al.  Rotavirus 2/6 Virus-Like Particles Administered Intranasally in Mice, with or without the Mucosal Adjuvants Cholera Toxin and Escherichia coli Heat-Labile Toxin, Induce a Th1/Th2-Like Immune Response , 2001, Journal of Virology.

[15]  T. Tumpey,et al.  Mucosal Delivery of Inactivated Influenza Vaccine Induces B-Cell-Dependent Heterosubtypic Cross-Protection against Lethal Influenza A H5N1 Virus Infection , 2001, Journal of Virology.

[16]  J. Rehg,et al.  Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. , 2002, The Journal of infectious diseases.

[17]  R. Compans,et al.  Mucosal Immunization with Virus-Like Particles of Simian Immunodeficiency Virus Conjugated with Cholera Toxin Subunit B , 2003, Journal of Virology.

[18]  S. Hamada,et al.  Influenza A Virus-Infected Hosts Boost an Invasive Type of Streptococcus pyogenes Infection in Mice , 2003, Journal of Virology.

[19]  K. Nichol,et al.  The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. , 2003, Vaccine.

[20]  S. Hamada,et al.  Vaccination with formalin-inactivated influenza vaccine protects mice against lethal influenza Streptococcus pyogenes superinfection. , 2004, Vaccine.

[21]  S. Hamada,et al.  The Streptococcus pyogenes Capsule Is Required for Adhesion of Bacteria to Virus-Infected Alveolar Epithelial Cells and Lethal Bacterial-Viral Superinfection , 2004, Infection and Immunity.

[22]  R. Belshe.  Current status of live attenuated influenza virus vaccine in the US. , 2004, Virus research.

[23]  T. Ichinohe,et al.  Synthetic Double-Stranded RNA Poly(I:C) Combined with Mucosal Vaccine Protects against Influenza Virus Infection , 2005, Journal of Virology.

[24]  M. Akashi,et al.  In vitro enzymatic degradation of nanoparticles prepared from hydrophobically-modified poly(gamma-glutamic acid). , 2005, Macromolecular bioscience.

[25]  M. Akashi,et al.  Preparation and characterization of biodegradable nanoparticles based on poly(gamma-glutamic acid) with l-phenylalanine as a protein carrier. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[26]  H. Kido,et al.  Modified Pulmonary Surfactant Is a Potent Adjuvant That Stimulates the Mucosal IgA Production in Response to the Influenza Virus Antigen1 , 2006, The Journal of Immunology.

[27]  M. Feldmann,et al.  Activation of NF-κB by the intracellular expression of NF-κB-inducing kinase acts as a powerful vaccine adjuvant , 2006, Proceedings of the National Academy of Sciences.

[28]  M. Akashi,et al.  Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity. , 2007, Vaccine.

[29]  M. Akashi,et al.  Targeting of Antigen to Dendritic Cells with Poly(γ-Glutamic Acid) Nanoparticles Induces Antigen-Specific Humoral and Cellular Immunity1 , 2007, The Journal of Immunology.

[30]  R. Compans,et al.  Induction of Heterosubtypic Immunity to Influenza Virus by Intranasal Immunization , 2007, Journal of Virology.